Jack CRJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. The lancet neurology. 2013;12.2: 207-216.
Article
CAS
Google Scholar
Gordon BA, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study. Lancet Neurol. 2018;17:241–50.
Article
Google Scholar
Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367:795–804. doi:https://doi.org/10.1056/NEJMoa1202753.
Article
CAS
Google Scholar
Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci. 1968;7:331–56.
Article
CAS
Google Scholar
Jansen WJ, et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurol. 2022. doi:https://doi.org/10.1001/jamaneurol.2021.5216.
Article
Google Scholar
Donohue MC, et al. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA. 2017;317:2305–16. doi:https://doi.org/10.1001/jama.2017.6669.
Article
CAS
Google Scholar
Sperling RA, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & dementia. 2011;7.3: 280-292.
Gatz M, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168–74. doi:https://doi.org/10.1001/archpsyc.63.2.168.
Article
Google Scholar
Dubois B, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimer’s Dement. 2016;12:292–323.
Article
Google Scholar
Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–3.
Article
CAS
Google Scholar
Caselli RJ, et al. Cognitive domain decline in healthy apolipoprotein E ε4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007;64:1306–11.
Article
Google Scholar
Lim YY, et al. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer’s disease. Neurobiol Aging. 2015;36:1239–44. doi:https://doi.org/10.1016/j.neurobiolaging.2014.12.008.
Article
CAS
Google Scholar
Bellenguez C, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nature genetics. 2022:1–25.
Scheltens P, et al. Alzheimer’s disease. The Lancet. 2021;397:1577–90.
Article
CAS
Google Scholar
Ebenau JL, et al. Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score. Alzheimer’s & Dementia: Diagnosis Assessment & Disease Monitoring. 2021;13:e12229.
Google Scholar
Darst BF, et al. Pathway-specific polygenic risk scores as predictors of amyloid-β deposition and cognitive function in a sample at increased risk for Alzheimer’s disease. J Alzheimers Dis. 2017;55:473–84.
Article
CAS
Google Scholar
Mormino EC, et al. Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology. 2016;87:481–8. doi:https://doi.org/10.1212/WNL.0000000000002922.
Article
CAS
Google Scholar
Porter T, et al. Utility of an Alzheimer’s disease risk-weighted polygenic risk score for predicting rates of cognitive decline in preclinical Alzheimer’s disease: a prospective longitudinal study. J Alzheimers Dis. 2018;66:1193–211.
Article
CAS
Google Scholar
Carrasquillo MM, et al. Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease. Neurobiol Aging. 2015;36:60–7.
Article
Google Scholar
Skoog I, et al. A non-APOE polygenic risk score for Alzheimer’s disease is associated with CSF neurofilament light in a representative sample of cognitively unimpaired 70-year-olds. The Journals of Gerontology: Series A (2021).
Marden JR, et al. Using an Alzheimer’s Disease polygenic risk score to predict memory decline in black and white Americans over 14 years of follow-up Running head: AD polygenic risk score predicting memory decline. Alzheimer Dis Assoc Disord. 2016;30:195.
Article
Google Scholar
Verhaaren BF, et al. Alzheimer’s disease genes and cognition in the nondemented general population. Biol Psychiatry. 2013;73:429–34.
Article
CAS
Google Scholar
Andrews SJ, Das D, Cherbuin N, Anstey KJ, Easteal S. Association of genetic risk factors with cognitive decline: the PATH through life project. Neurobiol Aging. 2016;41:150–8.
Article
CAS
Google Scholar
Riaz M, et al. Effect of APOE and a polygenic risk score on incident dementia and cognitive decline in a healthy older population. Aging Cell. 2021;20:e13384.
Article
CAS
Google Scholar
Ge T, et al. Dissociable influences of < em > APOE</em > ε4 and polygenic risk of AD dementia on amyloid and cognition. Neurology. 2018;90:e1605–12. doi:https://doi.org/10.1212/wnl.0000000000005415.
Article
CAS
Google Scholar
Tan CH, et al. Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition. Acta Neuropathol. 2018;135:85–93.
Article
CAS
Google Scholar
Cruchaga C, et al. Polygenic risk score of sporadic late-onset Alzheimer’s disease reveals a shared architecture with the familial and early-onset forms. Alzheimer’s Dement. 2018;14:205–14.
Article
Google Scholar
Konijnenberg E, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Res Ther. 2018;10:75. doi:https://doi.org/10.1186/s13195-018-0406-7.
Article
CAS
Google Scholar
Rabbitt PMA, et al. The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age, 1983 through 2003. Aging Neuropsychol Cognition. 2004;11:245–79. doi:https://doi.org/10.1080/13825580490511116.
Article
Google Scholar
Willemsen G, et al. The Adult Netherlands Twin Register: twenty-five years of survey and biological data collection. Twin Res Hum Genet. 2013;16:271–81. doi:https://doi.org/10.1017/thg.2012.140.
Article
Google Scholar
de Jager CA, Budge MM, Clarke R. Utility of TICS‐M for the assessment of cognitive function in older adults. International journal of geriatric psychiatry. 2003;18.4:318-324.
Article
Google Scholar
Morris, JC, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD): I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989
Morris, JC. Current vision and scoring rules the clinical dementia rating (CDR). Neurology. 1993;43:2412-2414.
Yesavage, JA, et al. Development and validation of a geriatric depression screening scale: a preliminary report. Journal of psychiatric research. 1982;17.1:37-49.
Article
Google Scholar
Saan R, Deelman B De 15-woordentest A en B (een voorlopige handleiding). Groningen: Afdeling Neuropsychologie, AZG (1986).
Rey A L’examen clinique en psychologie [Clinical psychological examination] Presses Universitaires de France. Paris, France (1964).
Meyers JE, Bayless JD, Meyers KR. Rey complex figure: memory error patterns and functional abilities. Applied Neuropsychology. 1996;3.2:89-92.
Article
CAS
Google Scholar
Snitz BE, et al. Cognitive trajectories associated with beta-amyloid deposition in the oldest-old without dementia. Neurology. 2013;80:1378–84. doi:https://doi.org/10.1212/WNL.0b013e31828c2fc8.
Article
CAS
Google Scholar
Reijs BLR, et al. Memory Correlates of Alzheimer’s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. J Alzheimers Dis. 2017;60:1119–28. doi:https://doi.org/10.3233/Jad-160766.
Article
CAS
Google Scholar
Robbins TW, et al. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dement Geriatr Cogn Disord. 1994;5:266–81.
Article
CAS
Google Scholar
Papp KV, et al. Development of a Psychometrically Equivalent Short Form of the Face-Name Associative Memory Exam for use Along the Early Alzheimer’s Disease Trajectory. Clin Neuropsychologist. 2014;28:771–85. doi:https://doi.org/10.1080/13854046.2014.911351.
Article
Google Scholar
Rentz, DM, et al. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011;49.9:2776-2783.
Reitan, RM. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and motor skills. 1958;8.3:271-276.
Wechsler, D. Wechsler adult intelligence scale-revised (WAIS-R). Psychological Corporation. 1981.
Schmand B, Groenink SC, van den Dungen M. [Letter fluency: psychometric properties and Dutch normative data]. Tijdschr Gerontol Geriatr. 2008;39:64–76. doi:https://doi.org/10.1007/bf03078128.
Article
CAS
Google Scholar
Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. J Neurol Neurosurg Psychiatry. 2002;73:126–33.
Article
CAS
Google Scholar
McKenna P, Warrington EK. J Neurol Neurosurg Psychiatry. 1980;43:781–8.
Article
CAS
Google Scholar
Van der Elst W, Van Boxtel MPJ, Van Breukelen GJP, Jolles J. The Stroop Color-Word Test: Influence of Age, Sex, and Education; and Normative Data for a Large Sample Across the Adult Age Range. Assessment. 2006;13:62–79. doi:https://doi.org/10.1177/1073191105283427.
Article
Google Scholar
Bird CM, Papadopoulou K, Ricciardelli P, Rossor MN, Cipolotti L. Monitoring cognitive changes: Psychometric properties of six cognitive tests. Br J Clin Psychol. 2004;43:197–210. doi:https://doi.org/10.1348/014466504323088051.
Article
Google Scholar
Bos I, et al. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimers Res Ther. 2018;10:64. doi:https://doi.org/10.1186/s13195-018-0396-5.
Article
CAS
Google Scholar
Hong S, et al. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry. 2020;10:403. doi:https://doi.org/10.1038/s41398-020-01074-z.
Article
CAS
Google Scholar
Tesi N, et al. Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease. Translational psychiatry. 2020;10:1–12.
Article
Google Scholar
Narasimhan V, et al. BCFtools/RoH: a hidden Markov model approach for detecting autozygosity from next-generation sequencing data. Bioinformatics. 2016;32:1749–51.
Article
CAS
Google Scholar
Delaneau O, Marchini J, Zagury J-F. A linear complexity phasing method for thousands of genomes. Nat Methods. 2012;9:179–81. doi:https://doi.org/10.1038/nmeth.1785.
Article
CAS
Google Scholar
Das S, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48:1284–7. doi:https://doi.org/10.1038/ng.3656.
Article
CAS
Google Scholar
McCarthy S, et al Haplotype Reference, C.(2016). A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet48, 1279–1283.
Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet. 2013;9:e1003348.
Article
CAS
Google Scholar
Nelissen N, et al. Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease. J Nucl Med. 2009;50:1251–9. doi:https://doi.org/10.2967/jnumed.109.063305.
Article
CAS
Google Scholar
Sibomana M, et al. in IEEE Symposium Conference Record Nuclear Science 2004. 2647–2651 (IEEE).
Collij L, et al. Assessing Amyloid Pathology in Cognitively Normal Subjects using [(18)F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. J Nucl Med. 2018. doi:https://doi.org/10.2967/jnumed.118.211532.
Article
Google Scholar
GEHealthcare. EPAR product information - summary of product characteristics. (2014).
Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67.
Article
Google Scholar
Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289–300.
Google Scholar
Sleegers K, et al. A 22-single nucleotide polymorphism Alzheimer’s disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42. Alzheimer’s Dement. 2015;11:1452–60.
Article
Google Scholar
Lopresti BJ, et al. Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. Neurobiol Aging. 2020;94:111–20.
Article
CAS
Google Scholar
Bellenguez C, et al New insights on the genetic etiology of Alzheimer’s and related dementia. MedRxiv (2020).
Konijnenberg E, et al. Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiol Aging. 2019;77:58–65.
Article
CAS
Google Scholar
Mortamais M, et al. Detecting cognitive changes in preclinical Alzheimer’s disease: A review of its feasibility. Alzheimer’s Dement. 2017;13:468–92. doi:https://doi.org/10.1016/j.jalz.2016.06.2365.
Article
Google Scholar
Doraiswamy PM, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79:1636–44.
Article
CAS
Google Scholar
Landau SM, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578–86.
Article
CAS
Google Scholar
De Jager PL, et al. A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging 33, 1017. e1011–7. e1015 (2012).
Article
Google Scholar
Mormino EC, et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82:1760–7.
Article
CAS
Google Scholar
International Genomics of Alzheimer’s Disease. C. Convergent genetic and expression data implicate immunity in Alzheimer’s disease. Alzheimers Dement. 2015;11:658–71. doi:https://doi.org/10.1016/j.jalz.2014.05.1757.
Article
Google Scholar
Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51:414–30.
Article
CAS
Google Scholar
Sims R, Hill M, Williams J. The multiplex model of the genetics of Alzheimer’s disease. Nat Neurosci. 2020;23:311–22. doi:https://doi.org/10.1038/s41593-020-0599-5.
Article
CAS
Google Scholar
Tomassen J, et al. Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2022;8:e12346. doi:https://doi.org/10.1002/trc2.12346.
Article
Google Scholar
Livingston G, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396:413–46. doi:https://doi.org/10.1016/S0140-6736(20)30367-6.
Article
Google Scholar
Villeneuve S, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138:2020–33.
Article
Google Scholar
Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Reviews Neurol. 2013;9:106–18.
Article
CAS
Google Scholar
Duncan L, et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun. 2019;10:1–9.
Article
CAS
Google Scholar
Vermunt L, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimer’s Dement. 2019;15:888–98.
Article
Google Scholar